8 weeks, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of WIB-801CE on inhibition of platelet aggregation.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002941

Enrollment

Registered

2018-06-20

Start date

2016-10-24

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Subjects will be randomized to receive WIB-801CE or placebo. Subjects will orally self-adminster WIB-801CE or placebo 1cap per day for 8weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Male and female subjects over 20 years of age inclusive 2) platelet aggregability(Collagen, Adenosine Diphosphate) over 70% 3) Subjects who agree the particpation in the trial and submit informed and consent before the beginning of the trial.

Exclusion criteria

Exclusion criteria: 1)Subjects with systolicBP = 160 mmHg or diastolicBP = 100 mmHg and also taking a beta blocker or a hydragogue. 2)Woman who are pregnant of lactating or planning to pregnant 3)Subjects which in the opinion investigator could affect preclude evluation of response

Design outcomes

Primary

Measure	Time frame
platelet aggregability(Collagen, Adenosine Diphosphate)	—

Secondary

Measure	Time frame
Thromboxane B2;Serotonin;C-Reactive Protein;Total cholesterol;Triglyceride;HDL-cholesterol;LDL-cholesterol	—

Countries

Korea, Republic of

Contacts

Public ContactBe Long Jo

Seoul National University Hospital

belong.cho@gmail.com+82-2-2072-2195

Outcome results